Increased Frequency of TIGIT+ CD4 T Cell Subset in Autoantibody-positive First-degree Relatives of Patients with Rheumatoid Arthritis
Overview
Authors
Affiliations
Background: Despite immune cell dysregulation being an important event preceding the onset of rheumatoid arthritis (RA), the phenotype of T and B cells in preclinical RA is less understood. The aim of this study was to characterize T and B cell populations in RA patients and their autoantibody (aAb) negative and positive first-degree relatives (FDR).
Methods: Cryopreserved peripheral blood mononuclear cells (PBMCs) collected at scheduled visits from aAb-(n=25), and aAb+ FDR (n=10) and RA patients (n=13) were thawed and stained using optimized antibody cocktails as per a specific 13-color T or B cell panel. Immunophenotyping was performed using a Cytoflex LX (Beckman-Coulter) flow cytometer and FlowJo software was used for analyzing the frequency of immune cell populations.
Results: Multicolor flow cytometry experiments identified an increased TIGIT expression in circulating lymphocytes of aAb+ FDR and RA patients, relative to aAb- FDR (P<0.01). These TIGIT T cells exhibited a memory phenotype and expressed high levels of PD-1, ICOS, HLA-DR, CXCR3 and CXCR5. Moreover, increased TIGIT CD4 T cell frequency correlated with the frequency of PD-1 CD4 T cells (r = 0.4705: = 0.0043) and circulating levels of ACPA and RF. We also identified a decreased frequency of CD27+IgD- switched memory B cells in RA patients ( < 0.01), while increased frequency of TIGIT+ CD4 T cells in FDR correlated with the frequency of PD1PTEN B cells (r = 0.6838, = 0.0004) and autoantibody positivity ( = 0.01).
Conclusion: We demonstrate TIGIT as a distinct CD4 T cell marker for differentiating aAb- FDR from aAb+FDR and might play a critical role in regulating T and B cell crosstalk in preclinical RA.
Dong C, Lin J, Wang Y, Zhu J, Lin L, Xu J Inflammation. 2024; .
PMID: 39088121 DOI: 10.1007/s10753-024-02115-1.
Wang C, Wu Y, Huang L, Zheng J, Chen J Cells. 2024; 13(5.
PMID: 38474367 PMC: 10931001. DOI: 10.3390/cells13050403.
Chemokines and chemokine receptors as promising targets in rheumatoid arthritis.
Murayama M, Shimizu J, Miyabe C, Yudo K, Miyabe Y Front Immunol. 2023; 14:1100869.
PMID: 36860872 PMC: 9968812. DOI: 10.3389/fimmu.2023.1100869.